Allogeneic Stem Cell Transplantation Clinical Trial
Official title:
Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation
- The primary objective of this study is to evaluate the efficacy and safety profile of
itraconazole as in primary prophylaxis
- The second objective of this study is to find the difference between long-term versus
short-term sequential therapy of Itraconazole (intravenous followed by oral
itraconazole) as primary prophylaxis of invasive fungal infections (IFI) in patients
undergoing allogeneic stem cell transplantation (allo-SCT)
- also to explore the relationship between the incidence of IFI with plasma
concentrations of itraconazole and hydroxy-itraconazole
Status | Recruiting |
Enrollment | 120 |
Est. completion date | March 2011 |
Est. primary completion date | December 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 14 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Man or woman between 14 and 60 years of age, inclusive - Patients who affected by hematological diseases, receiving allo-SCT - Patients with no previous proven or probable invasive fungal infections. Patients without microbiological evidence but with effective anti-fungal therapy history are inclusive - Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study Exclusion Criteria: - Currently taking the contra-indicated medications such as teldane, astemizol, cisapride and HMG-CoA reductase inhibitor(e.g. Simvastatin, lovastatin, oral Midazolam and Triazolam) - History of allergy or intolerance to imidazole or azoles anti-fungal agents (e.g. Fluconazol, Itraconazole, Ketoconazole, Miconazole, Clotrimazole) - Pregnant women, lactating women or women of child bearing potential without applying valid contraceptive measures - Patients with current cardiac dysfunction (especially with congestive heart failure) or with the history of congestive heart failure - Patients with severe liver dysfunction (aminotransferase levels >= 5 times the upper limit of normal and total bilirubin level >= 3mg/dL(51.3 µmol/L); or the severity of liver dysfunction does not match this criteria but the patient is in bad condition and not suitable for this trial( doctors make the decision); - Patients with renal insufficiency having serum Ccr level <30ml/min, calculated from the following formula: Male: Ccr (ml/min)=(140-age)×weight (kg) /(0.8136×Crea (µmol/L) ) Female:Ccr (ml/min)=(140-age)×weight (kg) ×0.85/(0.8136× Crea (µmol/L) ) - Patients received any experimental drug within 14 days before the planned start of treatment. - Patients with bad whole body status and not suitable for the trial (doctors make the decision) |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
China | Guangzhou General Hospital of Guangzhou Military Command | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Guangzhou General Hospital of Guangzhou Military Command | First Affiliated Hospital, Sun Yat-Sen University, Nanfang Hospital of Southern Medical University, Renmin Hospital of Zhongshan Guangdong, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhujiang Hospital |
China,
Chinese guideline for the diagnosis and management of IFI in patients with hematologic/maliglant tumor (revised). Chinese journal of internal medicine 2007,46(7):607-610.
Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, Nichols WG, Musher B, Corey L. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004 Feb 15;103(4):1527-33. Epub 2003 Oct 2. — View Citation
Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Territo MC. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003 May 6;138(9):705-13. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | efficacy evaluation | the success rate of prophylaxis therapy by itraconazole | 90 days | No |
Secondary | group difference evaluation | efficacy difference between long-term and short-term groups per success rate at day 90 | 90 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
Terminated |
NCT01185223 -
Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation
|
Phase 3 | |
Not yet recruiting |
NCT01212796 -
Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH
|
N/A | |
Terminated |
NCT00737113 -
Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant
|
Phase 1 | |
Recruiting |
NCT06028828 -
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Not yet recruiting |
NCT03964922 -
Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation
|
N/A | |
Completed |
NCT03467074 -
Role of Interferon-λ and Vaccine Response
|
||
Completed |
NCT02273024 -
Exercise Prior to Allogeneic Hematologic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT06093334 -
Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD
|
N/A | |
Recruiting |
NCT03286530 -
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
|
Phase 2 | |
Completed |
NCT01092026 -
Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells
|
N/A | |
Recruiting |
NCT00883714 -
Exercise During the Allogeneic Stem Cell Transplantation
|
Phase 3 | |
Completed |
NCT04628338 -
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
|
Early Phase 1 | |
Completed |
NCT06256341 -
HHV-6-specific T-cell Reconstitution Among Children and Adolescents After Allogeneic Stem.
|
||
Completed |
NCT05088941 -
Impact of COVID-19 Pandemic on Allogeneic Stem Cell Transplantation Organization : a French Experience
|
||
Not yet recruiting |
NCT06453460 -
Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla
|
Phase 2 | |
Recruiting |
NCT02533947 -
Cognition in Allogeneic Stem Cell Transplanted Patients and Sports
|
N/A | |
Completed |
NCT01560689 -
Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation
|
Phase 2 | |
Not yet recruiting |
NCT06297629 -
A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation
|
Phase 2 | |
Completed |
NCT01929980 -
Bortezomib to Treat Significant Complication of HSCT
|
Phase 2 |